Publications

Publications

Filter Results: (29) Arrow Down

Show Results For

McComb, Emily R.Remove McComb, Emily R. →

← Page 2 of 29 Results
  • March 2021 (Revised November 2022)
  • Case

Carnival Corp: Cruising In the Time of Covid

By: Emily R. McComb and Erik Stafford
Related
  • October 2020 (Revised December 2020)
  • Case

Investing at Pivotal Ventures

By: Emil N. Siriwardane, Emily R. McComb and Eren Kuzucu
Launched in 2015 by Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, Pivotal Ventures is an investment and incubation company. The company aims to support and promote transformational ideas, people and organizations, and advance social progress for women... View Details
Keywords: Investment; Management; Mission and Purpose; Venture Capital
Related
  • February 2020 (Revised February 2021)
  • Case

Growing Skoah

By: Emily McComb and Emily Williams
Related
  • February 2019 (Revised December 2019)
  • Case

The Bankruptcy of Cumulus Media

By: Emily McComb
Keywords: Bankruptcy
Related
  • April 2018
  • Supplement

Celgene

By: Malcolm Baker and Emily R. McComb
In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with... View Details
Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis
Related
  • March 2018 (Revised May 2018)
  • Case

Celgene

By: Malcolm Baker and Emily McComb
In February 2011, Adam Koppel, a managing director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with... View Details
Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry
Related
  • March 2018 (Revised May 2018)
  • Supplement

Celgene (B)

By: Malcolm Baker and Emily McComb
Supplements the (A) case. View Details
Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry
Related
  • January 2018 (Revised January 2019)
  • Supplement

Capital Allocation at HCA

By: W. Carl Kester and Emily R. McComb
Related
  • January 2018 (Revised April 2021)
  • Case

Capital Allocation at HCA

By: W. Carl Kester and Emily R. McComb
In early 2017, HCA Holdings, an investor-owned hospital management company, faced a strategically important capital allocation decision. After the exit of its private equity sponsors in 2016, HCA had to determine how best to allocate its substantial annual free cash... View Details
Keywords: Capital Allocation; Cash Distribution Policy; Dividends; Share Repurchases; Growth Strategy And Execution; Growth Investing; Capital Expenditures; Debt Management; Debt Reduction; Debt Policy; Hospital Management; Investor-owned Hospital Chains; Capital Budgeting; Capital Structure; Cash Flow; Corporate Finance; Decision Choices and Conditions; Health Industry; United States
Related